Search research articles
Contact Us
Filters
Showing results (101-110 of 118) with videos related to
Page
of 12
Sort By:
Signal Transduction and Targeted Therapy
|
February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
Cancer Discovery
|
May 11, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer
Jia-Tao Zhang, Si-Yang Liu, Wei Gao, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 28, 2017
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
Hai-Yan Tu, E-E Ke, Jin-Ji Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
Yang-Si Li, Qitao Yu, Qing Bu, et al.
The Lancet. Oncology
|
November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
JTO Clinical and Research Reports
|
January 3, 2022
Real-World Survival Outcomes Based on <i>EGFR</i> Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
Xue-Ning Yang, Hong-Hong Yan, Jun Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.
JAMA Oncology
|
June 13, 2024
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial
Song Dong, Zhen Wang, Jia-Tao Zhang, et al.
Eclinicalmedicine
|
October 2, 2023
Efficacy, safety and dose selection of AZD3759 in patients with untreated <i>EGFR</i>-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
Si-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, et al.
Clinical Lung Cancer
|
October 25, 2023
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)
Jia-Tao Zhang, Song Dong, Wei-Quan Gu, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 118) with videos related to
Sort By:
Page
of 12
Signal Transduction and Targeted Therapy
|
February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
Cancer Discovery
|
May 11, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer
Jia-Tao Zhang, Si-Yang Liu, Wei Gao, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 28, 2017
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
Hai-Yan Tu, E-E Ke, Jin-Ji Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
Yang-Si Li, Qitao Yu, Qing Bu, et al.
The Lancet. Oncology
|
November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
JTO Clinical and Research Reports
|
January 3, 2022
Real-World Survival Outcomes Based on <i>EGFR</i> Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
Xue-Ning Yang, Hong-Hong Yan, Jun Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.
JAMA Oncology
|
June 13, 2024
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial
Song Dong, Zhen Wang, Jia-Tao Zhang, et al.
Eclinicalmedicine
|
October 2, 2023
Efficacy, safety and dose selection of AZD3759 in patients with untreated <i>EGFR</i>-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
Si-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, et al.
Clinical Lung Cancer
|
October 25, 2023
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)
Jia-Tao Zhang, Song Dong, Wei-Quan Gu, et al.
Page
of 12